US 12,029,794 B2
Virus-like particle conjugates for diagnosis and treatment of tumors
Elisabet de los Pinos, Brookline, MA (US); John Todd Schiller, Kensington, MD (US); Rhonda C. Kines, Washington, DC (US); and John MacDougall, Hingham, MA (US)
Assigned to Biosciences, Inc., Boston, MA (US); and The United States of America, as represented by the Secretary, Department of Health and Human Serv., Bethesda, MD (US)
Filed by Aura Biosciences, Inc., Boston, MA (US); and The United States of America, as represented by the Secretary, Department of Health and Human Serv., Bethesda, MD (US)
Filed on Dec. 2, 2021, as Appl. No. 17/540,549.
Application 17/540,549 is a continuation of application No. 17/395,369, filed on Aug. 5, 2021.
Application 17/395,369 is a continuation of application No. 16/778,361, filed on Jan. 31, 2020, granted, now 11,110,181.
Application 16/778,361 is a continuation of application No. 16/143,147, filed on Sep. 26, 2018, granted, now 10,588,984.
Application 16/143,147 is a continuation of application No. 15/023,169, granted, now 10,117,947, previously published as PCT/US2014/056412, filed on Sep. 18, 2014.
Claims priority of provisional application 61/879,627, filed on Sep. 18, 2013.
Prior Publication US 2022/0088216 A1, Mar. 24, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/64 (2017.01); A61K 39/12 (2006.01); A61K 41/00 (2020.01); A61K 47/69 (2017.01); A61N 5/06 (2006.01); C07K 1/13 (2006.01); C07K 14/025 (2006.01); C07K 16/08 (2006.01); C07K 16/32 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01)
CPC A61K 47/6901 (2017.08) [A61K 39/12 (2013.01); A61K 41/0057 (2013.01); A61K 41/0071 (2013.01); A61K 47/64 (2017.08); A61N 5/062 (2013.01); C07K 1/13 (2013.01); C07K 14/025 (2013.01); C07K 16/084 (2013.01); C07K 16/32 (2013.01); C12N 7/00 (2013.01); A61K 2039/545 (2013.01); A61K 2039/585 (2013.01); C07K 2317/33 (2013.01); C07K 2317/76 (2013.01); C12N 2710/20023 (2013.01); C12N 2710/20033 (2013.01); C12N 2710/20034 (2013.01)] 28 Claims
OG exemplary drawing
 
1. A method comprising:
administering to a subject a virus-like particle (VLP) comprising viral capsid proteins and about 50 to about 1000 photosensitizer molecules, wherein the subject has cancerous cells; and
applying to the cancerous cells an infrared, near-infrared, or ultraviolet light that activates cytotoxicity of the photosensitizer molecules.